However, although the incidence of docetaxel-induced ILD was numerically higher in the post-ICI group than in the ICI-naïve group in the present study, NSCLC patients receiving docetaxel were more frequently treated with concomitant VEGF/VEGFR inhibitors in the post-ICI setting (60.7% vs 25.5%; Table 3). Here, VEGFA is linked to non-small cell lung carcinoma.